AYTU Stock Overview
Aytu Biopharma, Inc., a specialty pharmaceutical company, focuses on developing and commercializing novel therapeutics and consumer healthcare products the United States and internationally.
+ 1 more risk
Aytu BioPharma Competitors
Price History & Performance
|Historical stock prices|
|Current Share Price||US$0.19|
|52 Week High||US$2.99|
|52 Week Low||US$0.18|
|1 Month Change||-17.98%|
|3 Month Change||-72.30%|
|1 Year Change||-93.13%|
|3 Year Change||-98.29%|
|5 Year Change||-99.98%|
|Change since IPO||-100.00%|
Recent News & Updates
Aytu BioScience GAAP EPS of -$0.49 misses by $0.12, revenue of $27.45M beats by $1.95M
Aytu BioScience press release (NASDAQ:AYTU): FQ4 GAAP EPS of -$0.49 misses by $0.12. Revenue of $27.45M (+16.9% Y/Y) beats by $1.95M. Cash and cash equivalents at the end of the fiscal year ended June 30, 2022 were $19.4 million. Subsequent to the end of the year, the Company raised $10.0 million in gross proceeds in a registered public offering. Prescription segment Adjusted EBITDA was a positive $1.1 million, while Consumer Health was $(2.1) million resulting in a combined Adjusted EBITDA of $(1.0) million for the Company's commercial business. This compares to Adjusted EBITDA of $(5.5) million for the Prescription segment and $(2.7) million for the Consumer Health segment in Q4 2021, resulting in a combined Adjusted EBITDA of $(8.2) million for the Company's commercial business. Shares +5.26%.
Aytu Biopharma adds fourth patent license for AR101 to treat rare genetic disorder
Aytu BioPharma (NASDAQ:AYTU) announced on Wednesday the addition of a fourth patent for AR101/Enzastaurin to treat Vascular Ehlers-Danlos Syndrome, rare genetic disorder treatment. The patent has an expiry date of September 2041. The company expects to advance the PREVEnt Trial in VEDS for AR101 and dose the first patient by early 2023. "Adding this fourth patent to the portfolio deepens and broadens the intellectual property surrounding AR101/Enzastaurin for the treatment of inherited vascular disorders, including VEDS, for which we are advancing AR101 as an initial indication," the company said. Vascular Ehlers-Danlos syndrome (vEDS) is the most severe type of a hereditary disorder of the connective tissue. (AYTU) had risen 3.3% before the bell.
Aytu gets US patent for AR101/Enzastaurin for circulatory system disorders
Aytu BioPharma (NASDAQ:AYTU) said the U.S. Patent and Trademark Office issued a patent, a first for AR101/Enzastaurin. The U.S. patent No. 11,273,148 titled 'Targeted Epigenetic Therapy for Inherited Aortic Aneurism Condition,' covers methods for the targeted epigenetic therapy of inherited aortic aneurysm and other diseases with altered regulation of TGFβ genes, including Ehlers-Danlos Syndrome, the company said in an Aug. 16 press release. Aytu added that it was the first issued patent supporting the portfolio and expires in August of 2038, if not extended. "This issued patent underpins the broad potential clinical application across numerous inherited vascular disorders, including vascular Ehlers-Danlos Syndrome ("VEDS"), for which we are advancing AR101 as an initial indication. We expect to progress the PREVEnt Trial in VEDS for AR101 and dose the first patient by early 2023," said Aytu CEO Josh Disbrow. AYTU +0.59% to $0.29 premarket Aug. 16
|AYTU||US Pharmaceuticals||US Market|
Return vs Industry: AYTU underperformed the US Pharmaceuticals industry which returned 4.2% over the past year.
Return vs Market: AYTU underperformed the US Market which returned -22.1% over the past year.
|AYTU Average Weekly Movement||18.8%|
|Pharmaceuticals Industry Average Movement||11.5%|
|Market Average Movement||6.9%|
|10% most volatile stocks in US Market||15.8%|
|10% least volatile stocks in US Market||2.8%|
Stable Share Price: AYTU is more volatile than 90% of US stocks over the past 3 months, typically moving +/- 19% a week.
Volatility Over Time: AYTU's weekly volatility has increased from 13% to 19% over the past year.
About the Company
Aytu Biopharma, Inc., a specialty pharmaceutical company, focuses on developing and commercializing novel therapeutics and consumer healthcare products the United States and internationally. The company offers Adzenys XR-ODT for the treatment of attention deficit hyperactivity disorder (ADHD) in patients from six years and older; and Cotempla XR-ODT for the treatment of ADHD in patients from six to seventeen years old. It also provides Karbinal ER, a carbinoxamine oral suspension for the treatment of seasonal and perennial allergies; and Poly-Vi-Flor and Tri-Vi-Flor prescription supplements for infants and children for the treatment of fluoride deficiency.
Aytu BioPharma Fundamentals Summary
|AYTU fundamental statistics|
Is AYTU overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|AYTU income statement (TTM)|
|Cost of Revenue||US$44.39m|
Last Reported Earnings
Jun 30, 2022
Next Earnings Date
|Earnings per share (EPS)||-1.76|
|Net Profit Margin||-113.97%|
How did AYTU perform over the long term?See historical performance and comparison
Is AYTU undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score 5/6
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Below Fair Value
Significantly Below Fair Value
Key Valuation Metric
Which metric is best to use when looking at relative valuation for AYTU?
Other financial metrics that can be useful for relative valuation.
|What is AYTU's n/a Ratio?|
Price to Sales Ratio vs Peers
How does AYTU's PS Ratio compare to its peers?
|AYTU PS Ratio vs Peers|
|Company||PS||Estimated Growth||Market Cap|
CURR CURE Pharmaceutical Holding
BMMJ Body and Mind
UNRV Unrivaled Brands
CANB Can B
AYTU Aytu BioPharma
Price-To-Sales vs Peers: AYTU is good value based on its Price-To-Sales Ratio (0.1x) compared to the peer average (1.4x).
Price to Earnings Ratio vs Industry
How does AYTU's PE Ratio compare vs other companies in the US Pharmaceuticals Industry?
Price-To-Sales vs Industry: AYTU is good value based on its Price-To-Sales Ratio (0.1x) compared to the US Pharmaceuticals industry average (2.7x)
Price to Sales Ratio vs Fair Ratio
What is AYTU's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
|Current PS Ratio||0.1x|
|Fair PS Ratio||2.2x|
Price-To-Sales vs Fair Ratio: AYTU is good value based on its Price-To-Sales Ratio (0.1x) compared to the estimated Fair Price-To-Sales Ratio (2.2x).
Share Price vs Fair Value
What is the Fair Price of AYTU when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: AYTU ($0.19) is trading below our estimate of fair value ($7.48)
Significantly Below Fair Value: AYTU is trading below fair value by more than 20%.
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Analyst Forecast: Target price is more than 20% higher than the current share price, but there are not enough analysts covering the stock to determine statistical confidence in agreement.
Discover undervalued companies
How is Aytu BioPharma forecast to perform in the next 1 to 3 years based on estimates from 2 analysts?
Future Growth Score1/6
Future Growth Score 1/6
Earnings vs Savings Rate
Earnings vs Market
High Growth Earnings
Revenue vs Market
High Growth Revenue
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: AYTU is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: AYTU is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: AYTU is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: AYTU's revenue (8.7% per year) is forecast to grow faster than the US market (7.6% per year).
High Growth Revenue: AYTU's revenue (8.7% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if AYTU's Return on Equity is forecast to be high in 3 years time
Discover growth companies
How has Aytu BioPharma performed over the past 5 years?
Past Performance Score0/6
Past Performance Score 0/6
Growing Profit Margin
Earnings vs Industry
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: AYTU is currently unprofitable.
Growing Profit Margin: AYTU is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: AYTU is unprofitable, and losses have increased over the past 5 years at a rate of 44.6% per year.
Accelerating Growth: Unable to compare AYTU's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: AYTU is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (5%).
Return on Equity
High ROE: AYTU has a negative Return on Equity (-239.03%), as it is currently unprofitable.
Discover strong past performing companies
How is Aytu BioPharma's financial position?
Financial Health Score2/6
Financial Health Score 2/6
Short Term Liabilities
Long Term Liabilities
Stable Cash Runway
Forecast Cash Runway
Financial Position Analysis
Short Term Liabilities: AYTU's short term assets ($59.9M) do not cover its short term liabilities ($64.4M).
Long Term Liabilities: AYTU's short term assets ($59.9M) exceed its long term liabilities ($27.1M).
Debt to Equity History and Analysis
Debt Level: AYTU has more cash than its total debt.
Reducing Debt: Insufficient data to determine if AYTU's debt to equity ratio has reduced over the past 5 years.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: AYTU has less than a year of cash runway based on its current free cash flow.
Forecast Cash Runway: AYTU has less than a year of cash runway if free cash flow continues to reduce at historical rates of 12.6% each year
Discover healthy companies
What is Aytu BioPharma current dividend yield, its reliability and sustainability?
Dividend Score 0/6
Cash Flow Coverage
Dividend Yield vs Market
|Aytu BioPharma Dividend Yield vs Market|
|Company (Aytu BioPharma)||n/a|
|Market Bottom 25% (US)||1.6%|
|Market Top 25% (US)||4.6%|
|Industry Average (Pharmaceuticals)||2.5%|
|Analyst forecast in 3 Years (Aytu BioPharma)||n/a|
Notable Dividend: Unable to evaluate AYTU's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate AYTU's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if AYTU's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if AYTU's dividend payments have been increasing.
Earnings Payout to Shareholders
Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Cash Payout to Shareholders
Cash Flow Coverage: Unable to calculate sustainability of dividends as AYTU has not reported any payouts.
Discover strong dividend paying companies
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Josh Disbrow (47 yo)
Mr. Joshua R. Disbrow, also known as Josh, is Chairman of the Board at Aytu Biopharma, Inc. (formerly known as Aytu BioScience, Inc.) since July 2016 and serves as its Chief Executive Officer. He serves as...
CEO Compensation Analysis
|Josh Disbrow's Compensation vs Aytu BioPharma Earnings|
|Date||Total Comp.||Salary||Company Earnings|
|Jun 30 2022||n/a||n/a|
|Mar 31 2022||n/a||n/a|
|Dec 31 2021||n/a||n/a|
|Sep 30 2021||n/a||n/a|
|Jun 30 2021||US$6m||US$545k|
|Mar 31 2021||n/a||n/a|
|Dec 31 2020||n/a||n/a|
|Sep 30 2020||n/a||n/a|
|Jun 30 2020||US$2m||US$608k|
|Mar 31 2020||n/a||n/a|
|Dec 31 2019||n/a||n/a|
|Sep 30 2019||n/a||n/a|
|Jun 30 2019||US$1m||US$330k|
|Mar 31 2019||n/a||n/a|
|Dec 31 2018||n/a||n/a|
|Sep 30 2018||n/a||n/a|
|Jun 30 2018||US$606k||US$303k|
|Mar 31 2018||n/a||n/a|
|Dec 31 2017||n/a||n/a|
|Sep 30 2017||n/a||n/a|
|Jun 30 2017||US$1m||US$250k|
|Mar 31 2017||n/a||n/a|
|Dec 31 2016||n/a||n/a|
|Sep 30 2016||n/a||n/a|
|Jun 30 2016||US$1m||US$250k|
Compensation vs Market: Josh's total compensation ($USD6.20M) is above average for companies of similar size in the US market ($USD784.47K).
Compensation vs Earnings: Josh's compensation has increased whilst the company is unprofitable.
Experienced Management: AYTU's management team is not considered experienced ( 1.4 years average tenure), which suggests a new team.
Experienced Board: AYTU's board of directors are considered experienced (6.3 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
|Owner Type||Number of Shares||Ownership Percentage|
Dilution of Shares: Shareholders have been substantially diluted in the past year, with total shares outstanding growing by 126.6%.
|Ownership||Name||Shares||Current Value||Change %||Portfolio %|
Aytu BioPharma, Inc.'s employee growth, exchange listings and data sources
- Name: Aytu BioPharma, Inc.
- Ticker: AYTU
- Exchange: NasdaqCM
- Founded: 2015
- Industry: Pharmaceuticals
- Sector: Pharmaceuticals & Biotech
- Implied Market Cap: US$11.931m
- Shares outstanding: 62.43m
- Website: https://aytubio.com
Number of Employees
- Aytu BioPharma, Inc.
- 373 Inverness Parkway
- Suite 206
- United States
|Ticker||Exchange||Primary Security||Security Type||Country||Currency||Listed on|
|AYTU||NasdaqCM (Nasdaq Capital Market)||Yes||Common Stock||US||USD||Apr 2015|
|AY2||DB (Deutsche Boerse AG)||Yes||Common Stock||DE||EUR||Apr 2015|
|0A8M||LSE (London Stock Exchange)||Yes||Common Stock||GB||USD||Apr 2015|
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2022/09/28 00:00|
|End of Day Share Price||2022/09/28 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.